新型佐剂增强复制缺陷型人巨细胞病毒疫苗在非人灵长类中引发的免疫应答
该临床前研究在成年恒河猴中评估两种新型佐剂(Advax微颗粒,含或不含TLR9激动剂CpG寡核苷酸;以及默克公司专有脂质纳米颗粒LNP)对低剂量V160(10单位)复制缺陷型人巨细胞病毒疫苗免疫应答的影响,并与高剂量V160(100单位)单独免疫进行比较。两种佐剂在所试剂量下均未显著改善体液免疫应答,但均增强细胞免疫应答:Advax促进CD4+和CD8+ T细胞,LNP主要影响CD4+ T细胞。转录组分析显示两者作用机制不同。
要点
- 两种佐剂在所试剂量下均未显著增强V160疫苗的体液免疫应答。
- Advax促进CD4+和CD8+ T细胞应答,LNP主要影响CD4+ T细胞应答。
- LNP在接种后1天诱导 innate 免疫相关基因上调,Advax不激活已知炎症通路且至第7天才影响基因表达。
核心结论
- Advax和LNP两种佐剂在所试剂量下均未显著改善V160疫苗诱发的体液免疫应答,但均增强细胞免疫应答。
- Advax促进CD4+和CD8+ T细胞应答,LNP主要影响CD4+ T细胞应答。
- 转录组分析表明两种佐剂作用机制不同:LNP诱导类似病毒感染的先天免疫基因上调,Advax呈非炎症性独特机制。
- 数据支持进一步在临床试验中探索Advax和LNP作为需要同时诱导体液和T细胞应答的疫苗佐剂。
研究设计与样本
- 临床前研究,在成年恒河猴中比较低剂量V160(10单位)单独或联合佐剂与高剂量V160(100单位)单独免疫的免疫应答。
- 两种新型佐剂分别为:delta菊粉微颗粒Advax(含或不含TLR9激动剂CpG寡核苷酸)和默克公司专有脂质纳米颗粒(LNP)。
主要发现
- 两种佐剂在所试剂量下均未显著改善V160疫苗诱发的体液免疫应答。
- Advax促进CD4+和CD8+ T细胞应答,LNP主要影响CD4+ T细胞应答。
- 接种后1天,LNP诱导大量参与先天免疫应答的基因上调,类似病毒感染触发的基因。
- Advax不激活任何已知炎症通路,直至给药后第7天才显著影响基因表达模式。
临床怎么用
- 作者认为数据支持进一步在临床试验中探索Advax和LNP作为需要同时诱导体液和T细胞应答的疫苗佐剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adjuvants have long been explored to enhance vaccine efficacy. Current adjuvants approved for human vaccines are mostly studied for their ability to improve antibody responses. There remains a need for development of novel adjuvants, especially those able to enhance cell-mediated immunity (CMI). In this preclinical study we assessed the effect of two novel adjuvants, a delta inulin microparticle Advax formulated with or without a toll-like receptor 9 (TLR9) agonist CpG oligonucleotide, and a Merck & Co., Inc., Kenilworth, NJ, USA proprietary lipid nanoparticle (LNP), on immune responses elicited by V160, an experimental replication-defective human cytomegalovirus vaccine. Adult rhesus macaques were immunized with a low dose of V160 (10 units) either alone or in combination with the adjuvants as compared to those immunized with a high dose of V160 alone (100 units). While neither adjuvant conferred a significant benefit to vaccine-elicited humoral immune responses at the dose tested, both enhanced cellular immune responses to V160, where Advax promoted both CD4+ and CD8+ T cells and LNP predominantly impacted the CD4+ T cell response. Transcriptome analyses of peripheral blood samples demonstrated different modes of action for these adjuvants. One day post vaccination, LNP induced upregulation of a large number of genes involved in the innate immune response similar to those triggered by viral infection. In contrast, Advax did not activate any known inflammatory pathways and did not significantly impact gene expression pattern until day 7 post administration, suggesting a unique, non-inflammatory mechanism. These data warrant further exploration of Advax and LNP as adjuvants in clinical trials for vaccines desiring to elicit both humoral and T cell responses.
引用
- Li H, Monslow MA, Freed DC, et al. Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates. Vaccine. 2021. PMID: 34852943. doi:10.1016/j.vaccine.2021.10.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。